Filing Flows

Filing Flows › ARS Pharmaceuticals (SPRY) › Next earnings date

ARS Pharmaceuticals (SPRY) earnings: missed the estimate

ARS Pharmaceuticals (SPRY) reported on Nov 5, 2026 and missed the EPS estimate: −$0.36 against −$0.33 (-8.0%). Revenue was $37.7M for Q3 2026, +16% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−8.0% vs estimate
Beat rate20%

The last report

ARS Pharmaceuticals reported revenue of $37.7M for the third quarter 2026 (+16% Y/Y), net loss $35.6M: Product $33.4M, Revenue Under Supply Agreements $2.6M, Revenue Under Collaboration Agreements $1.7M. How it makes money → · Every quarter →

ARS Pharmaceuticals: EPS against the estimate, last 5 reportsARS Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.49−$0.52Nov 25−$0.48−$0.42Mar 26−$0.54−$0.61May 26−$0.49−$0.63Aug 26−$0.33−$0.36Nov 26
Latest (Nov 26): Estimate −$0.33, Reported −$0.36.

ARS Pharmaceuticals' latest quarter

ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did ARS Pharmaceuticals beat earnings?

ARS Pharmaceuticals (SPRY) reported on Nov 5, 2026 and missed the EPS estimate: −$0.36 against −$0.33 (-8.0%).

When does SPRY report earnings?

The next date is not set yet.

Does ARS Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.